Silo Pharma to Present at Psychedelic Drug Development Conference
April 24, 2023 08:15 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
March 27, 2023 09:00 ET
|
Silo Pharma, Inc.
SPU-26 Pain Management Using Ketamine Composition Action supports planned IND package submission to FDA for SP-26 ENGLEWOOD CLIFFS, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 15, 2023 08:40 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
February 13, 2023 08:35 ET
|
Silo Pharma, Inc.
Patent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic ENGLEWOOD CLIFFS, NJ, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02, 2023 08:50 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Announces Stock Repurchase Program
January 31, 2023 07:45 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 10, 2023 10:15 ET
|
Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30, 2022 08:10 ET
|
Silo Pharma, Inc.
SPU-21 effective in controlling arthritis progression. SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 ...
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 01, 2022 09:00 ET
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...